$BBIO

BridgeBio Pharma (BBIO) is the focus. Barclays analyst Eliana Merle reiterated an overweight rating and a $157 price target, citing Attruby, an FDA-approved heart drug. In Q1 2026, U.S. Attruby revenue was $180.6 million and total revenue $194.5 million. Barclays projects $912 million U.S. sales for 2026 versus $826 million consensus, with FDA decisions on BBP-418 (Nov 27, 2026) and Encaleret (May 8, 2027).

Yahoo Finance lists a filing for BioXcel Therapeutics (BBIO). The item is an S-3ASR filing dated Jul 24, 2026, with related exhibits shown, including filing fees and other referenced documents. The update indicates an offering registration with the SEC.

Yahoo Finance reports that BioLife Solutions (BBIO) filed an S-8 registration statement with the SEC on July 24, 2026. The filing includes related exhibits such as EX-23.1 and EX-5.1, and references filing fees. The update is relevant for investors tracking BBIO’s equity offering or compensation-related registrations.

BridgeBio Pharma (BBIO) said the FDA accepted its filing for encaleret, an oral investigational drug for autosomal dominant hypocalcemia type 1 (ADH1). A decision is expected by May 8, 2027. The company cited phase III CALIBRATE results and noted the FDA is not planning an advisory committee meeting. BBIO shares are up 8% YTD.

BridgeBio Pharma said the FDA accepted its New Drug Application for encaleret, intended as a potential first treatment for autosomal dominant hypocalcemia type 1 (ADH1). The FDA target decision date is May 8, 2027. BridgeBio cited trial results showing efficacy and safety without routine calcium or vitamin D supplements, and is also studying pediatric ADH1 and chronic hypoparathyroidism.

BridgeBio Pharma (NASDAQ:BBIO) said the FDA accepted its New Drug Application for encaleret, for autosomal dominant hypocalcemia type 1. The FDA set a PDUFA action date of May 8, 2027 and does not plan an advisory committee meeting. The filing is based on Phase 3 CALIBRATE results meeting endpoints. BridgeBio plans EMA submission in 2H 2026.

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

Ellis Andrea sold 17,167 shares of BridgeBio Pharma, Inc. (BBIO) at $84.00 ($1.44M total) on 2026-07-09 under a Rule 10b5-1 trading plan.

Cook Jennifer E. sold 148,589 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $88.54 ($84.00–$90.00, $13.16M total) across 2 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Biotech stocks hit 52-week highs on July 9, 2026. First Track Biotherapeutics (TRAX) rose 55.99% to $32.40 on Phase 1 trial starts and an FDA end-of-Phase 2 meeting. BridgeBio Pharma (BBIO) closed at $93.52, up 15.12%, citing Acoramidis and Phase 3 plans. Monopar (MNPR), 10x Genomics (TXG) and MapLight (MPLT) also reached highs amid clinical updates.